Timusamin
Thymus cytamin — Khavinson-school organ peptide fraction, oral tablet
Timusamin (Thymus cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal thymus, 155mg per tablet. The immune claim is restoration of an age-shifted lymphocyte subset distribution. The manufacturer's own 2023 paper states that the active substances of the injectable thymus drug are two dipeptides, KE and EW — both of which are sold separately, on this same site, as defined compounds with their own pages.
Timusamin quick facts
| Route | Oral |
| Frequency | Not established · Not established |
| Half-life | Not characterized — no analytical method for this preparation has been published |
| Forms | Oral |
| Evidence level | No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school. |
If the extract's activity really reduces to two dipeptides, the oral question becomes specific and answerable: dipeptides have a named carrier route across the intestinal wall through PEPT1 and PEPT2, and a 155mg nucleoprotein complex does not. Nobody has assayed this tablet for either dipeptide, and a PubMed search for its name on 8 September 2026 returned zero records. A CD4/CD8 ratio and NK cell count before and after a pack is the read-out the class claim implies and nobody has published one.
How Timusamin works
A Khavinson-school polypeptide fraction from animal thymus, 155mg per tablet. The immune claim is restoration of an age-shifted lymphocyte subset distribution. The manufacturer's own 2023 paper states that the active substances of the injectable thymus drug are two dipeptides, KE and EW — both of which are sold separately, on this same site, as defined compounds with their own pages.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Timusamin
Buy Timusamin at RUPharma →The evidence for Timusamin
Graded by what exists behind each claim.
✅ Clinically validated
- None, and the zero is the finding. A PubTator3 search of PubMed for this product's name, run 8 September 2026, returned zero records — no trial, no case series, no pharmacokinetic study, no adverse-event report. A search for the class word *cytamins* returns exactly one record, a Russian nutrition review that lists them among categories of bioactive substances for liver disease. There has never been a setting in which a result of any kind could have been recorded for this tablet, which is a different statement from a clean record.
📊 Correlative data
- The thymus extract Thymalin, given parenterally, carries the oldest human claims in this school — an immune-response report in vaccinated subjects in a 1988 Soviet military medical journal (Degtiarev 1988) and immune-status regulation in severely ill older patients (Kuznik 2021). Different product, different route, and an evidentiary standard set by the era it was published in.
- The manufacturer's own 2023 paper says the drug is two dipeptides — KE and EW — both of which are sold separately on this site as defined compounds (Linkova 2023).
🧪 Theoretical / extrapolated
- That dipeptide finding turns the oral question into a specific one: di- and tripeptides have a named carrier route across the intestinal wall through PEPT1 and PEPT2, and the school has assessed transport feasibility for 26 of its own ultrashort peptides (Khavinson 2023). A 155 mg nucleoprotein complex has no comparable route.
- Which points somewhere awkward for this product: the defined dipeptides are the version whose absorption can be reasoned about, and the extract is the version whose cannot.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Timusamin actually does
The manufacturer's own research group has published what it thinks the thymus extract actually is, and it changes what an oral version of it would have to achieve. Linkova 2023 names KE and EW — two dipeptides — as the active substances of the thymus drug. Not an undefined fraction. Two molecules, each two amino acids long, each of which is sold separately under its own name and has its own page on this site. If that paper is right, the interesting question about a thymus tablet is not what is in it. It is whether those two dipeptides get across the gut.
And that question has a real literature, which is unusual for anything on this shelf. Khavinson 2023 assessed the feasibility of transporting 26 biologically active ultrashort peptides through the peptide transporters PEPT1 and PEPT2. Those are genuine, well-characterized intestinal and renal carriers whose physiological job is moving di- and tripeptides across an epithelium; they are the reason certain peptide drugs are orally active at all. A dipeptide has a named, plausible route across the gut wall. A 155 mg nucleoprotein complex does not.
Which produces the sharpest sentence on this page, and it is unflattering to the product. The school's own two findings, put side by side, say that the active principle is a pair of dipeptides and that dipeptides have a carrier-mediated oral route. The conclusion that follows is that the defined dipeptides are the sensible way to take this orally and the extract is the version whose absorption nobody can account for. Both papers come from the manufacturer's side of the table.
The product, plainly. A 155 mg tablet of a nucleoprotein fraction from animal thymus, 40 per pack, listed by a partner at $45. No composition, no dipeptide assay, no dissolution data, no statement of source species.
Cell, rodent, human — and where it stops
The search first. PubTator3, this product's name alone, 8 September 2026: zero records. The class word returns one nutrition review Tokaev 2007. Nothing has been published on this tablet.
That class search used one of two transliterations and missed the other. Cytamines returns eleven records against one for cytamins. Four concern this line: servicemen Khavinson 2001, athletes Emirova 2004, a manufacturing paper Ryzhak 2003, and a later sports-recovery study Rozhkova 2007. Corrected 9 September 2026.
For a thymus product the manufacturing paper is the one that matters, and it cuts two ways. Ryzhak 2003 reports that the class is made from organs of young animals and that testing by World Health Organization methods indicates absence of infectious agents, proto-oncogenes, nucleic acids and prion proteins. It is the only published answer to the question a calf-thymus tablet raises, and it is the developers describing their own process, which is a conflict worth naming rather than hiding. What it is not is evidence that the tablet does anything. The athletics paper Emirova 2004 names hepatamin, epifamin and suprenamin; there is no thymus tablet in it, and no immune endpoint in either human paper.
The extract literature that does exist is the oldest human record in the whole school. Degtiarev 1988 reported Thymalin used to stimulate the immune response in vaccinated subjects — a 1988 report in a Soviet military medical journal, which is worth saying out loud because it sets the evidentiary standard of the era rather than of today. Kuznik 2021 reports regulation of immune status in severely ill older patients. Khavinson 2003 is the long-running claim that thymus and pineal peptides extend human life. All of it concerns Thymalin, given parenterally.
The explant rung named the thymus explicitly. Khavinson 2002 applied thymus extract to explants of rat thymus and reported tissue-matched stimulation; Ryzhak 2015 did the same with calf-derived Thymalin at 0.01 to 100 ng/ml on organotypic cultures from young and old rats. Real experiments, in a dish, with the material applied directly.
Where it stops, and the stopping point is specific rather than general. On most pages in this cohort the break is “the human data belongs to the injectable”. Here there is a second, sharper break: the two dipeptides Linkova 2023 says do the work have never been assayed in this tablet, so nobody knows whether the oral product contains a meaningful quantity of them, and nobody has measured either dipeptide in blood after any oral dose of anything. The transporter paper establishes that the route could exist. It does not establish that this product uses it.
Timusamin pharmacokinetics — how much of it actually gets in
What degrades it, and why the answer is different from every other page in this cohort. The complex meets the same acid, pepsin, trypsin and brush-border peptidase sequence as any dietary protein. But if the school is right that the activity resides in two dipeptides, then proteolysis is not purely destructive here — digestion of a protein fraction produces di- and tripeptides, which is precisely the substrate class PEPT1 carries Khavinson 2023. This is the one product on the cytamin shelf where the gut could in principle be doing part of the manufacturing rather than all of the destroying. It is an argument, not a finding, and it is labeled as one.
The oral barrier, with the mechanism named. PEPT1 is a proton-coupled, low-affinity high-capacity transporter on the intestinal brush border; PEPT2 is its high-affinity relative in the kidney. Their substrate range covers essentially all di- and tripeptides regardless of sequence, which is why they carry beta-lactam antibiotics and angiotensin-converting-enzyme inhibitor prodrugs across the gut wall. A 2-residue peptide is therefore not facing the absorption problem a 10-residue one faces.
The arithmetic that bounds the dipeptide claim. KE has a molecular weight of roughly 276 Da and EW roughly 334 Da. If a 155 mg tablet were, generously, 1% dipeptide by mass and all of it were absorbed into 5 liters, the peak would be about 310 ng/ml, or roughly 1 micromolar. That is a real concentration and it sits above the 0.01-100 ng/ml band used in the explant work Ryzhak 2015. The number that is missing is the first one: nobody has published what fraction of the tablet is dipeptide. Every figure after that is arithmetic on an unmeasured input.
The comparator, and it is available here. The same manufacturer sells the parenteral extract, and the site sells both dipeptides for injection under their own names. So unlike the thyroid page in this cohort, this product has two stronger siblings to be compared against — and no comparison of a tablet against an injection of either has ever been published.
What would have to be true, and how you would know it was not
Four predictions. The immune system is measurable, which makes them unusually concrete.
1. A lymphocyte subset panel before and after a pack. CD4/CD8 ratio and NK cell count, drawn at baseline and at the end of 40 tablets. The class's entire immune claim is that thymic peptides restore an age-shifted subset distribution, and this panel is the direct read-out of that claim. Zero published studies of this tablet have run it.
2. Against the product: the dipeptides will beat the extract, and they are cheaper. If Linkova 2023 is right, then a defined dose of KE or EW should reproduce whatever the extract does, with a known quantity instead of an unknown one. Prediction: a head-to-head on the CD4/CD8 endpoint shows the defined peptides equal or better. Nobody has run it, and the result would make the extract the least attractive of three products the same company sells.
3. Vaccination is the cleanest available human test and it is already routine. The oldest claim in this literature is that thymus peptide improves the response to a vaccine Degtiarev 1988. Antibody titre before and four weeks after any scheduled vaccination, with and without a course, is an ordinary immunology measurement with a hard endpoint. It has not been repeated in the thirty-eight years since.
4. The prediction that fails quietly. In a healthy adult under 40, a CD4/CD8 ratio and NK count are already inside the reference range and have nowhere useful to move. The explant work reports its effects as age-dependent. So the honest expectation for the population most likely to buy this is no measurable change — and anyone reporting a large one should check for an intercurrent infection before crediting the tablet.
What nobody has tested yet
Nobody has assayed the tablet for the two molecules its own manufacturer says are the active substances. Linkova 2023 names KE and EW. A liquid-chromatography run against synthetic standards would say how much of each is in a 155 mg tablet, and whether the answer is micrograms or nothing. It is the single cheapest, most decisive experiment available on any product in this cohort, and it has never been reported.
Nobody has measured either dipeptide in blood after an oral dose. The transporter paper argues the route is feasible Khavinson 2023; feasibility is not measurement. One volunteer, one tablet, serial plasma sampling and a targeted mass spectrometry method would convert the central claim of this page from an argument into a number.
Nobody has repeated the vaccine experiment. Degtiarev 1988 is a 1988 report from a system that no longer exists, with a design nobody would accept today, on a question that modern immunology could answer in one season with pre-registered titres. Thirty-eight years, zero replications, and the claim is still in circulation.
Extrapolation, labeled as such. If the mechanism is carrier-mediated dipeptide absorption, three consequences follow that have not been looked for: absorption should be saturable, so doubling the tablet count should less than double the plasma level; it should be reduced by taking the tablet with a protein-rich meal, because dietary di- and tripeptides compete for the same carrier; and it should be higher in a fasted state. All three are testable with the same assay that does not yet exist, and none is mentioned by any vendor selling dosing instructions for this product.
Timusamin — its own safety story, not its class's
Three things specific to an oral thymus preparation.
An immune product's risk is the mirror image of its claim. Anything argued to raise immune activity is, by the same argument, a concern in autoimmune disease and in transplant recipients on deliberate immunosuppression. Nobody has studied this tablet in either population, and the class literature is about restoring an age-shifted balance rather than about raising activity in a normal one Khavinson 2003. That distinction is doing a lot of work and it has never been tested in a person taking this product.
Animal thymus is lymphoid tissue and the sourcing question is real. No vendor publishes the source species, country of origin or processing controls. That is not evidence of a problem; it is the absence of the information that would let a buyer evaluate one, and it is a gap the two synthetic dipeptides do not have.
What zero means, said once more because it keeps mattering. There are no published adverse events for this tablet and no published studies of it, so the empty column measures the literature. The parenteral relative has decades of reported use, almost all of it single-group, Russian-language and outside any modern adverse-event reporting system Kuznik 2021. Long use without systematic collection is a weaker form of reassurance than it sounds, and it is the strongest form available here.
Sources read for this page
- Khavinson VKh, Cherniak SI, D'iakonov MM. [Cytamines--preparations for maintaining high professional ability and longevity in servicemen]. Voenno-Meditsinskii Zhurnal 2001 [Russian] · PMID 11338817
- Emirova LR, Rozhkova EA, Paniushkin VV, Mirzoian RS, Seifulla NR. [The effects of cytamines and their combinations with ecdystene, apilak, vitamax, and essentiale on the work capability of athletes]. Eksperimental'naia i Klinicheskaia Farmakologiia 2004 [Russian] · PMID 15341074
- Ryzhak GA, Nekrasov PA, Kiselev OI, Khavinson VKh. Study of protein components of natural peptide regulators. Bulletin of Experimental Biology and Medicine 2003 · PMID 12717513
- Rozhkova EA, Ordzhonikidze ZG, Druzhinin AE, Seifulla NR, Paniushkin VV, Kuznetsov IuM. [Using carnosine and natural antioxidants for the prophylaxis of acute post-loading oxidative stress]. Eksperimental'naia i Klinicheskaia Farmakologiia 2007 [Russian] · PMID 18074807
- Linkova N. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. International Journal of Molecular Sciences 2023 · PMID 37686182
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Degtiarev AA. Use of thymalin in stimulating an immune response in subjects inoculated with influenza vaccine. Voenno-Meditsinskii Zhurnal 1988 [Russian] · PMID 3206835
- Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology 2021;11(4):368–376
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters 2003;24(3-4):233–240 · PMID 14523363
- Tokaev ES. [Bioactive substance used for treatment and preventive maintenance of liver diseases]. Voprosy Pitaniia 2007 [Russian] · PMID 17802767
Timusamin — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Timusamin — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Timusamin moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Timusamin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Timusamin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Timusamin — frequently asked questions
What is Timusamin?
Timusamin (Thymus cytamin — Khavinson-school organ peptide fraction, oral tablet) is a longevity & bioregulators research compound. A Khavinson-school polypeptide fraction from animal thymus, 155mg per tablet. The immune claim is restoration of an age-shifted lymphocyte subset distribution. The manufacturer's own 2023 paper states that the active substances of the injectable thymus drug are two dipeptides, KE and EW — both of which are sold separately, on this same site, as defined compounds with their own pages.
Where can I find Timusamin dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Timusamin protocol are available to members inside Skool. This public page covers what Timusamin is, how it works and the evidence.
What is the half-life of Timusamin?
Timusamin has an approximate half-life of Not characterized — no analytical method for this preparation has been published, which is part of what determines how often it's dosed.
What's the evidence behind Timusamin?
Current evidence level: No published study of this product. The literature belongs to the parenteral extracts and the synthetic peptides of the same school.. Timusamin is offered for research purposes only and is not an approved medicine.
What Timusamin is used for
Timusamin appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.